Besifloxacin HCl
(Synonyms: 盐酸贝西沙星) 目录号 : GC15920An ophthalmologic fluoroquinolone antibiotic
Cas No.:405165-61-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Besifloxacin hydrochloride is a fourth-generation fluoroquinolone antibiotic. IC50 Value:Target: AntibacterialBesifloxacin has been found to inhibit production of pro-inflammatory cytokines in vitro. Besifloxacin is a novel 8-chloro-fluoroquinolone agent with potent, bactericidal activity against prevalent and drug-resistant pathogens.besifloxacin is the most potent agent tested against gram-positive pathogens and anaerobes and is generally equivalent to comparator fluoroquinolones in activity against most gram-negative pathogens. Besifloxacin demonstrates potent, broad-spectrum activity, which is particularly notable against gram-positive and gram-negative isolates that are resistant to other fluoroquinolones and classes of antibacterial agents.
References:
[1]. Wang Z, Wang S, Zhu F, Chen Z, Yu L, Zeng S.Determination of enantiomeric impurity in besifloxacin hydrochloride by chiral high-performance liquid chromatography with precolumn derivatization.Chirality. 2012 Jul;24(7):526-31. doi: 10.1002/chir.22042.
[2]. Hussar DA.New drugs: golimumab, besifloxacin hydrochloride, and artemether/lumefantrine.J Am Pharm Assoc (2003). 2009 Jul-Aug;49(4):570-4.
[3]. Nafziger AN, Bertino JS Jr.Besifloxacin ophthalmic suspension for bacterial conjunctivitis.Drugs Today (Barc). 2009 Aug;45(8):577-88.
[4]. Proksch JW, Ward KW.Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.J Ocul Pharmacol Ther. 2010 Oct;26(5):449-58.
[5]. Comstock TL, Paterno MR, Usner DW, Pichichero ME.Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.Paediatr Drugs. 2010 Apr 1;12(2):105-12. doi: 10.2165/11534380-000000000-00000.
Cas No. | 405165-61-9 | SDF | |
别名 | 盐酸贝西沙星 | ||
化学名 | 7-[(3R)-3-aminoazepan-1-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid;hydrochloride | ||
Canonical SMILES | C1CCN(CC(C1)N)C2=C(C=C3C(=C2Cl)N(C=C(C3=O)C(=O)O)C4CC4)F.Cl | ||
分子式 | C19H22Cl2FN3O3 | 分子量 | 430.3 |
溶解度 | ≥ 4.3mg/mL in Water with ultrasonic and warming, <4.3mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.324 mL | 11.6198 mL | 23.2396 mL |
5 mM | 0.4648 mL | 2.324 mL | 4.6479 mL |
10 mM | 0.2324 mL | 1.162 mL | 2.324 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。